Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $37.80.

GMAB has been the topic of several research reports. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. HC Wainwright reissued a “buy” rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a report on Monday, July 28th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC boosted its holdings in Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after purchasing an additional 1,464 shares in the last quarter. CWM LLC lifted its position in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after buying an additional 603 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after buying an additional 1,070 shares in the last quarter. Barclays PLC grew its position in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Genmab A/S in the fourth quarter valued at $60,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Up 0.5%

Shares of NASDAQ GMAB opened at $21.78 on Friday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $28.43. The company has a market cap of $13.97 billion, a P/E ratio of 12.38, a P/E/G ratio of 6.58 and a beta of 0.95. The business’s 50 day moving average is $21.66 and its two-hundred day moving average is $20.83.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. Sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.